Osteoarthritis (OA) is characterized by destruction of the cartilage matrix, which results in impairment of articular joint function. Degradation of the matrix proteoglycan aggrecan is an early event, crucial for the development of OA lesions (1), and inhibitors of aggrecan breakdown therefore have therapeutic potential as disease-modifying agents for OA (2). Analysis of synovial fluids and cartilage lesions of patients with OA indicates that matrix metalloproteinases (MMPs) and aggrecanases, which are members of the adamalysin with thrombospondin motifs (ADAMTS) family, are the main aggrecan-degrading enzymes (3-5). Among them, ADAMTS-5 (aggrecanase 2) appears to be a major aggrecanase in mice (6, 7), but both ADAMTS-4 (aggrecanase 1) and ADAMTS-5 are considered to play a role in human disease (8). Thus interest has been growing in the development of inhibitors for ADAMTS-4 and -5 (9 -11), mirroring the development of MMP inhibitors for the treatment of diseases associated with elevated MMP activity. Numerous MMP inhibitors have been developed, and several were clinically tested in patients with cancer (12) and rheumatoid arthritis (13), but they failed to show efficacy and exhibited side effects such as musculoskeletal pain and mild thrombocytopenia (12). These failures are thought to be due to the lack of selectivity of the inhibitors and inhibition of biologically important off-target metalloproteinases and other effects. Selectivity is thus a prerequisite for nontoxic therapeutic inhibitors.
Osteoarthritis (OA) is characterized by destruction of the cartilage matrix, which results in impairment of articular joint function. Degradation of the matrix proteoglycan aggrecan is an early event, crucial for the development of OA lesions (1) , and inhibitors of aggrecan breakdown therefore have therapeutic potential as disease-modifying agents for OA (2) . Analysis of synovial fluids and cartilage lesions of patients with OA indicates that matrix metalloproteinases (MMPs) and aggrecanases, which are members of the adamalysin with thrombospondin motifs (ADAMTS) family, are the main aggrecan-degrading enzymes (3) (4) (5) . Among them, ADAMTS-5 (aggrecanase 2) appears to be a major aggrecanase in mice (6, 7), but both ADAMTS-4 (aggrecanase 1) and ADAMTS-5 are considered to play a role in human disease (8) . Thus interest has been growing in the development of inhibitors for ADAMTS-4 and -5 (9 -11) , mirroring the development of MMP inhibitors for the treatment of diseases associated with elevated MMP activity. Numerous MMP inhibitors have been developed, and several were clinically tested in patients with cancer (12) and rheumatoid arthritis (13) , but they failed to show efficacy and exhibited side effects such as musculoskeletal pain and mild thrombocytopenia (12) . These failures are thought to be due to the lack of selectivity of the inhibitors and inhibition of biologically important off-target metalloproteinases and other effects. Selectivity is thus a prerequisite for nontoxic therapeutic inhibitors.
One way to increase selectivity against specific metalloproteinases is to generate exosite or allosteric inhibitors. MMPs and ADAMTSs are multidomain proteins, and in many cases their noncatalytic domains play an important role in recognition and effective cleavage of their natural extracellular matrix (ECM) substrates. For example, collagenases (MMP-1, MMP-8, and MMP-13) require their hemopexin domain to cleave triple helical collagen (14) , and the noncatalytic ancillary domains of ADAMTS-4 and -5 are essential for cleaving aggrecan core protein (15) (16) (17) . Molecules that bind to an enzyme exosite block interaction with natural ECM substrates and are an attractive alternative to active sitedirected inhibitors because they can be highly specific and effectively block hydrolysis only of the target substrate, thus minimizing in vivo side effects.
Calcium pentosan polysulfate (CaPPS) is a calcium salt form of chemically sulfated beechwood xylosan, with a molecular mass of 4000 -6000 Da. It has previously been shown to be an effective antiarthritic agent in various animal models and in some human OA trials (18 -20) . Although the mechanism of its action was not fully understood, CaPPS has been shown to block aggrecan breakdown (21) . It was also reported that CaPPS increases production of the endogenous aggrecanase inhibitor tissue inhibitor of metalloproteinases (TIMP)-3 by rheumatoid synovial (22) and gingival fibroblasts (23) . At about that time, we found that TIMP-3 is a potent inhibitor of ADAMTS-4 and -5 (24) and showed that TIMP-3 effectively blocks aggrecan breakdown in interleukin (IL) -1␣-stimulated cartilage in culture (25) . From these observations we postulated that CaPPS blocks aggrecan breakdown by increasing TIMP-3 levels in the cartilage. In this report we show that CaPPS indeed increases TIMP-3 levels in the cartilage without changing its mRNA levels. We found that this increase is due to blockade of TIMP-3 endocytosis, which is mediated by low-density lipoprotein receptor-related protein (LRP). In addition, CaPPS directly inhibits the aggrecanase activity of ADAMTS-4 and -5 as an exosite inhibitor. Furthermore, CaPPS greatly enhances TIMP-3 affinity for ADAMTS-4 and -5 but not for MMPs. These unique properties of CaPPS provide a new paradigm for the development of novel types of antiosteoarthritic agents.
MATERIALS AND METHODS

Reagents and antibodies
CaPPS was from Arthropharm (Sydney, Australia). Porcine heparin, desulfated porcine heparin, human hyaluronan, and type 1A bacterial collagenase were from Sigma-Aldrich (Dorset, UK). Bovine chondroitin-4-sulfate and all-trans retinoic acid were from Fluka (Seelze, Germany). Porcine dermatan sulfate was from Calbiochem (San Diego, CA, USA). Sucrose octasulfate was from Toronto Research Chemicals (North York, ON, Canada). Chondroitinase ABC and keratanase were from Seikagaku (Tokyo, Japan). Recombinant human IL-1␣ was kindly provided by Prof. J. Saklatvala (Kennedy Institute of Rheumatology, London, UK). Bovine nasal aggrecan (26), human receptor-associated protein (RAP) (27) , and human ADAMTS-4 and -5 (15-17) were prepared as described previously. Recombinant human TIMP-3 was expressed in HEK293 using a pCEP4-based expression vector (Invitrogen, Paisley, UK) kindly provided by Prof. M. Seiki (University of Tokyo, Japan). TIMP-3-containing medium was prepared by incubating cells with 250 nM RAP in serum-free Dulbecco modified Eagle medium (DMEM) for 36 h and concentrating the medium 10-fold. TIMP-3 concentration was determined by titration against a known concentration of the catalytic domain of MMP-1 using a fluorescent substrate enzyme assay. A recombinant interglobular domain of human aggrecan ( 330 YTGED to HLPGG 458 ) tagged with glutathione S-transferase and FLAG was expressed in Escherichia coli (unpublished results). The 2-B-6 antibody that recognizes deglycosylated aggrecan fragments (28) , BC-3 antibody that recognizes the N-terminal ARGSV generated by aggrecanase cleavage of the bovine aggrecan core protein at the Glu 373 -Ala 374 bond (29) , and BC-14 antibody that recognizes the N-terminal FFGVG generated by MMP cleavage of bovine aggrecan at Ser 341 -Phe 342 (30) were kind gifts from Prof. B. Caterson and Dr. C. Hughes (University of Cardiff, Cardiff, UK). The anti-GELE antibody that recognizes the C-terminal GELE generated by aggrecanase cleavage of bovine aggrecan at Glu 1480 -Gly 1481 has been previously described (16) . The rabbit anti-AGEG antibody that recognizes the N-terminal AGEG generated by aggrecanase cleavage of bovine aggrecan at Glu 1771 -Ala 1772 was raised in a rabbit against the aggrecan peptide sequence AGEGPSGGC (amino acids 1772 to 1778, amino acids in italics not part of the aggrecan sequence but added to link the peptide to keyhole limpet hemocyanin). Mouse anti-TIMP-3 antibodies were from Daiichi Fine Chemicals (136 -13H4, Toyama, Japan; used at 1:1000 for all experiments except cartilage extraction) and R&D Systems (MAB9731, Minneapolis, MN, USA; used at 1:1000 to analyze cartilage extracts). Sheep anti-TIMP-1 and anti-TIMP-2 have been previously described (31, 32) .
Human and porcine cartilage explant cultures
Human osteoarthritic cartilage was obtained from patients undergoing joint replacement surgery at Heatherwood and Wexham Park Hospitals (Slough, UK) and the Orthopaedic Surgery Department of Charing Cross Hospital (London, UK) with the consent of patients and the East Berkshire and Riverside Research Ethics Committees. Human and porcine (25) cartilage explants were grown (5% CO 2 , 37°C) in serum-free DMEM for 3 d with 1 M all-trans retinoic acid or IL-1␣ (10 ng/ml), respectively, either with or without CaPPS. Glycosaminoglycan released into the medium was measured using the dimethylenemethylene blue assay (33) . Aggrecan fragments in the medium were deglycosylated overnight with chondroitinase ABC and keratanase (0.01 U each/10 g dry weight of aggrecan) and analyzed by Western blotting.
Extraction of TIMP-3 from cartilage matrix
Cartilage explants (4 g cartilage/treatment) were dissected from porcine metacarpophalangeal joints and treated with IL-1␣ (10 ng/ml) with or without CaPPS (50 g/ml) in 20 ml of serum-free DMEM for 3 d. The conditioned media were concentrated by precipitation with 5% trichloroacetic acid. The cartilage was extracted for 4 d at 4°C with 10 ml of 4 M guanidine hydrochloride, 50 mM sodium acetate (pH 5.8) with 5 mM EDTA, 1 mM p-aminoethylbenzene sulfonyl fluoride, and 10 M E-64. The extracts were passed through a cell strainer, CsCl was added to give a final density of 1.5 g/ml, and the mixture was ultracentrifuged (26) . After centrifugation, the top 3/5 of the gradient was dialyzed against 50 mM Tris HCl (pH 7.5) with 150 mM NaCl, and proteins were precipitated with trichloroacetic acid. Equivalent volumes of conditioned medium and cartilage extract were analyzed by Western blotting using anti-TIMP-1, anti-TIMP-2, and anti-TIMP-3 antibodies.
Chondrocyte and HTB94 chondrosarcoma cell culture
Primary porcine chondrocytes were prepared by digesting cartilage with type 1A bacterial collagenase. Chondrocytes were passed through a cell strainer, washed twice, and plated in DMEM with 10% fetal calf serum. HTB94 human chondrosarcoma cells (American Culture Type Collection, Manassas, VA) were maintained in DMEM with 10% fetal calf serum, 100 U/ml penicillin, and 100 U/ml streptomycin. After treatment of cells with various concentrations of glycosaminoglycans for 8 to 36 h, conditioned media were concen-trated 50-fold by trichloroacetic acid precipitation and analyzed by Western blotting.
To determine the amount of matrix-associated TIMP-3, HTB94 cells were treated with 100 g/ml CaPPS or heparin in serum-free DMEM for 36 h, and conditioned media were concentrated by trichloroacetic acid precipitation. Cells attached to the culture flask were dissociated with EDTA. The ECM remaining in the culture flask was solubilized with reducing SDS sample buffer. TIMP-3 levels in equivalent volumes of each sample were analyzed by Western blotting.
Analysis of mRNA levels by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR)
mRNAs from HTB94 cells and HTB94 cells transfected with TIMP-3/pCEP4 plasmid were isolated using a QIAamp RNA Blood Minikit (Qiagen Ltd, Crawley, UK). mRNAs were extracted from cartilage samples using a BioPulverizer (BioSpec Products, Bartlesville, IA, USA) and TRI Reagent ® (Helena Biosciences, Gateshead, UK). Levels of TIMP-3 and 18S rRNA were quantified (nϭ3) by quantitative RT-PCR on a Rotor-Gene 6000 (Corbett Research, Cambridge, UK) using a SuperScript III Platinum One-Step qRT-PCR System (Invitrogen) with validated 6-carboxyfluorescein (FAM) -labeled primers for human TIMP-3 (TaqMan Gene Expression Assay; Applied Biosystems, Foster City, CA, USA) and 18S rRNA (LUX primer set, Invitrogen). A standard curve was constructed relating nanograms of RNA to C T values. Standardized C T values (ng TIMP-3 mRNA/ng 18S rRNA) are given relative to control untreated HTB94 cells (defined as 1) and were analyzed using a paired t test.
Assays for ADAMTS-4 and -5 and MMP activity
The activities of ADAMTS-4 and -5 were measured against aggrecan and the recombinant aggrecan IGD domain flanked by glutathione S-transferase at the N terminus and FLAG peptide at the C terminus (gst-IGD-flag) as described previously (17) . Briefly, aggrecan (50 g) was incubated with various isoforms of ADAMTS-4 or -5, and the reaction was terminated by 50 mM EDTA. The products were deglycosylated overnight with chondroitinase ABC and keratanase and analyzed by Western blotting using the BC-3 antibody. ADAMTS-4 or -5 activities were also measured using 17 M gst-IGD-flag. The reactions were terminated with 20 mM EDTA, and products were analyzed by densitometric analysis of SDS-PAGE gels. Activities of MMP-2 and -13 were measured using the fluorescent quenched peptide substrate (7- 
Effect of CaPPS on TIMP-3 inhibition of aggrecanases
values of TIMP-3 for various isoforms of ADAMTS-4 and -5 were determined under equilibrium kinetic conditions (35) . The effect of CaPPS on TIMP-3 inhibition of ADAMTS-4 and -5 was measured by incubating the enzymes with various concentrations of TIMP-3 in the presence or absence of 0.05 g/ml CaPPS for 1 h at 37°C and residual activity against gst-IGD-flag determined. K i(app) values of TIMP-3 for MMP-2 and -13 were similarly determined under equilibrium kinetic conditions using the fluorescent peptide substrate (34).
Timp3-null mouse cartilage explant culture
Femoral head cartilage from 3-wk-old wild-type or Timp3-null mice (36) was stimulated with 10 ng/ml IL-1␣ with or without CaPPS (50 or 100 g/ml) in serum-free DMEM for 3 d. Aggrecan breakdown was monitored by Western blotting with the 2-B-6 antibody.
RESULTS
CaPPS inhibits aggrecanase activity in porcine and human cartilage
CaPPS has been reported to protect bovine and human cartilage against aggrecan breakdown (21) . We tested whether this inhibition is due to suppression of MMP and/or ADAMTS activities. Treatment of cultured porcine cartilage explants with IL-1␣ caused a 4-fold increase in glycosaminoglycan release into the medium, and this increase was dose-dependently inhibited by CaPPS (Fig. 1A) . Further analysis of aggrecan breakdown products with neoepitope antibodies that recognize aggrecanase-dependent cleavage of the Glu 373 -Ala 374 bond (anti-ARGSV) and the Glu 1480 -Gly 1481 bond (anti-GELE), as well as a neoepitope antibody recognizing MMP-dependent cleavage at the Ser 341 -Phe 342 bond (anti-FFGVG), indicated that aggrecan was primarily degraded by aggrecanases and that these were effectively inhibited by CaPPS (Fig. 1B) . CaPPS similarly blocked glycosaminoglycan release in explants of human OA cartilage stimulated with retinoic acid (Fig.  1C) . This protection was also due to inhibition of aggrecanase activity (Fig. 1D) . Similar protection was seen with cartilage from 3 other OA patients.
CaPPS increases TIMP-3 levels in cartilage and in conditioned medium of cultured cells
Because the major aggrecanases, ADAMTS-4 and -5, are inhibited by TIMP-3 and not the other TIMPs (24), we tested our hypothesis that CaPPS inhibition of aggrecanase activity in cartilage is due to an increase of TIMP-3 in the tissue. Porcine cartilage explants in culture were treated with IL-1␣ and/or CaPPS for 3 d and the levels of TIMP-1, -2, and -3 in the cartilage and conditioned medium examined. TIMP-3 was present almost exclusively within the cartilage explants. Treatment with IL-1␣ did not alter the level of TIMP-3, but treatment with CaPPS increased TIMP-3 levels ϳ3.5-fold in the cartilage, estimated from pixel density (Fig.  2) . TIMP-1 and -2 were present primarily in the conditioned medium, and their levels were unaffected by IL-1␣ or CaPPS. We were unable to determine the effects of CaPPS on production of ADAMTS-4 and -5 because their levels in our cartilage extracts were too low to detect by Western blot.
To investigate the mechanism underlying the increase in TIMP-3 protein levels in cartilage, we examined the production of TIMP-3 by cultured primary porcine chondrocytes. TIMP-3 was not detectable in the conditioned medium of untreated chondrocytes (Fig.  3A) , but addition of CaPPS caused an increase in TIMP-3 levels in the medium. Addition of heparin to chondrocytes also resulted in an accumulation of TIMP-3 in the medium (Fig. 3A) . Similar results were observed with HTB94 chondrosarcoma cells; CaPPS and heparin dose-dependently increased TIMP-3 in the medium, with CaPPS and heparin having half maximal effective concentrations (EC 50 ) of 10 and 25 g/ml, respectively (Fig. 3B ). TIMP-3 was detectable in the conditioned medium 2-4 h after addition of CaPPS or heparin, with levels increasing to a maximum by 18 h (data not shown). TIMP-3 accumulation was reversible; after removal of CaPPS or heparin from the medium, TIMP-3 was undetectable within 24 -48 h (data not shown). When heparin-Sepharose beads were added to cells, TIMP-3 accumulated on the beads (data not shown), indicating that it interacts directly with sulfated glycosaminoglycans. Glycosaminoglycans with low levels of sulfation (chondroitin or dermatan sulfate) or no sulfation (hyaluronan) did not support TIMP-3 accumulation, and desulfation of heparin greatly reduced TIMP-3 accumulation (Fig. 3C) . Levels of TIMP-1 and -2 were not affected by CaPPS or heparin treatment.
We then examined whether the increase in TIMP-3 levels in the cartilage and medium was due to increased transcription. Quantitative reverse transcription PCR indicated that treatment of HTB94 cells with CaPPS (50 g/ml) had no effect on TIMP-3 mRNA levels (paired t test, Pϭ0.0603, Fig. 4A ). When these cells were transfected with a vector to overexpress TIMP-3, TIMP-3 mRNA levels increased 50-fold (Pϭ0.02). Addition of CaPPS to transfected cells did not significantly affect TIMP-3 mRNA levels (Pϭ0.1295), but TIMP-3 protein was detected in the medium only when CaPPS was added. CaPPS also had no effect on TIMP-3 mRNA medium was assessed by the dimethylenemethylene blue assay (shown as the averageϮsd of triplicate assays, nϭ3) (C) and aggrecan neoepitope antibodies (D). Release of aggrecan fragments into the conditioned medium was assessed by the dimethylenemethylene blue assay (A) and by Western blotting using neoepitope antibodies that recognize aggrecan fragments generated by aggrecanases (anti-ARGV and anti-GELE) and MMPs (anti-FFGVG) (B). C, D) Human (female, 74-yr-old) osteoarthritic cartilage explants were cultured for 3 d in serum-free DMEM in the presence of 1 M all-trans retinoic acid (RA) and/or 10 -100 g/ml CaPPS. Release of aggrecan fragments into the conditioned Figure 2 . Effects of CaPPS on cartilage TIMP-3. Porcine cartilage explants were cultured for 3 d in serum-free DMEM with IL-1␣ and/or 50 g/ml CaPPS. Conditioned media were concentrated by trichloroacetic acid precipitation. Cartilage extracts were prepared using guanidine hydrochloride and gradient density centrifugation. TIMP levels in equivalent volumes of medium and cartilage extracts were analyzed by Western blotting. levels in cartilage explants, either alone or in combination with IL-1␣ (PϾ0.35 for all, Fig. 4B ).
LRP-mediated endocytosis of TIMP-3
Heparin has been reported to solubilize TIMP-3 from the ECM (37), so we tested whether the observed accumulation of TIMP-3 in the HTB94 medium was due to solubilization of matrix-bound material. Without heparin or CaPPS treatment, very little TIMP-3 was detectable, either in the matrix, within cells, or in their conditioned medium (Fig. 5A) . Addition of 100 g/ml CaPPS or heparin for 36 h resulted in a marked accumulation of TIMP-3 in the medium, but no change in TIMP-3 levels in the cells or matrix. These results, together with CaPPS having no effect on TIMP-3 mRNA levels, suggested that newly synthesized and secreted TIMP-3 is rapidly endocytosed by the cell and that CaPPS and heparin sequester TIMP-3 in the medium by blocking this process.
To test the possibility of TIMP-3 endocytosis, we first used cytochalasin D, which blocks the pathway of endocytosis by inhibiting actin polymerization. This treatment caused an accumulation of TIMP-3 in the medium of HTB94 (Fig. 5B) , suggesting that TIMP-3 is normally internalized by the cell after secretion. We postulated that this process is mediated by LRP, a scavenger receptor that has been shown to internalize a number of proteinases and their inhibitors (38) . We therefore tested whether an antagonist of ligand binding to members of the LRP family, RAP, causes an increase in TIMP-3 in the medium. As shown in Fig. 5B , TIMP-3 was readily detected in the medium in the presence of RAP. These results indicate that TIMP-3 is normally internalized into cells by a member of the LRP family and that CaPPS and heparin block TIMP-3 binding to LRP and thus sequester TIMP-3 in the extracellular milieu. 
CaPPS directly inhibits ADAMTS-4 and -5 as an exosite inhibitor
We next tested whether CaPPS directly inhibits ADAMTS-4 and -5 activity, first using recombinant aggrecan interglobular domain (IGD) expressed in E. coli as a substrate to detect inhibition. As shown in Fig.  6C , no inhibition of full-length ADAMTS-4 (TS4 -1) was observed, even at 500 g/ml CaPPS. In contrast, when hydrolysis of native aggrecan at the Glu 373 -Ala 374 site in the interglobular domain was monitored, ADAMTS-4 (TS4 -1) was inhibited by CaPPS, with an inhibitory concentration 50 (IC 50 ) value of 0.2 g/ml (40 nM) (Fig. 6C) . Similarly, only weak inhibition of full-length ADAMTS-5 (TS5-1) by CaPPS was observed with the recombinant IGD substrate (IC 50 value 3 g/ml; 600 nM), but inhibition was greatly improved when the interglobular domain of aggrecan was used as a substrate, with an IC 50 value of 0.05 g/ml (10 nM) (Fig.  6D) . CaPPS also blocked aggrecanase activity in the chondroitin sulfate-rich region of aggrecan, with an IC 50 value of 0.05 g/ml for inhibition of ADAMTS5-1 hydrolysis at the Glu 1771 -Ala 1772 site (data not shown). We postulated that aggrecan substrate-specific inhibition of the aggrecanases by CaPPS is due to interaction of CaPPS with the noncatalytic domains of the ADAMTSs, preventing recognition of aggrecan by these domains. We have previously shown that the spacer (Sp) domain of ADAMTS-4 (16) and the cysteine-rich (CysR) domain of ADAMTS-5 (15) are the primary sites that interact with the sulfated polysaccharide chains of aggrecan. We therefore tested whether deletion of the C-terminal domains of the aggrecanases reduces the inhibitory ability of CaPPS. As shown in Fig. 6E , the IC 50 value of ADAMTS4 -2, which lacks the Sp domain, was 15 g/ml (3 M), compared to 0.2 g/ml (40 nM) for ADAMTS4 -1. For ADAMTS-5, deletion of the second thrombospondin and Sp domains had little effect on CaPPS inhibition, but deletion of the CysR domain increased the IC 50 from 0.05 g/ml (10 nM) to 15 g/ml (3 M) (Fig. 6F) . These results indicate that CaPPS specifically interacts with the Sp domain of ADAMTS-4 and with the CysR domain of ADAMTS-5 and as such is the first example for an exosite inhibitor of this class of enzymes.
We then tested whether other sulfated glycosaminoglycans have a similar exosite inhibitor activity for ADAMTS-4 and -5. Among the compounds we tested, heparin weakly inhibited full-length ADAMTS-5 activity against aggrecan, but it was 400-fold weaker than CaPPS, with an IC 50 of 20 g/ml ( Table 1) . Glycosaminoglycans with lower levels of sulfation (chondroitin-4-sulfate, dermatan sulfate) or no sulfation (hyaluronan) were ineffective. The highly sulfated disaccharide sucrose octasulfate was also not an effective inhibitor, indicating that high levels of sulfation alone were not sufficient for inhibitory activity. These results indicate that interaction of CaPPS with the noncatalytic exosites of ADAMTS-4 and -5 is specific. Furthermore, CaPPS had little effect on the activity of MMP-1, -2, or -13 against a peptide substrate, the recombinant IGD substrate or aggrecan, with IC 50 values greater than 20 g/ml (4 M) in all cases (data not shown). This indicates that CaPPS's inhibitory effects are not a phenomenon general to metalloproteinases.
CaPPS enhances TIMP-3 affinity for full-length ADAMTS-4 and -5
Because our data indicated that CaPPS interacts with both TIMP-3 and ADAMTS-4 and -5, we investigated whether CaPPS altered the affinity between TIMP-3 and aggrecanases. In this case we used the E. coli-expressed IGD substrate to measure enzyme activity. In the absence of CaPPS, K i(app) values of TIMP-3 for full-length ADAMTS-4 and -5 were 2 and 0.5 nM, respectively (Fig.  7A, B) . In the presence of 0.05 g/ml CaPPS, a concentration that does not directly inhibit ADAMTS-4
Figure 6. CaPPS is an exosite inhibitor of ADAMTS-4 and -5). A, B) Schematic representation of forms of ADAMTS-4 (A) and ADAMTS-5 used (B). C, D)
Substrate-dependent inhibition of full-length ADAMTS-4 (TS4 -1, 5 nM) (C) and ADAMTS-5 (TS5-1, 0.5 nM) (D) by CaPPS. The enzymes were preincubated with CaPPS for 1 h at 37°C, and residual activity against a recombinant gst-IGD-flag substrate (E) or aggrecan (F) was measured. IC 50 values for ADAMTS-4 and -5 using gst-IGD-flag were Ͼ1000 and 3 g/ml, respectively. IC 50 values for ADAMTS-4 and -5 using native aggrecan were 0.2 g/ml (40 nM) and 0.05 g/ml (10 nM), respectively. E) Inhibition of ADAMTS4 -1 (5 nM, F) and TS4 -2 (10 nM, E) by CaPPS, measured using aggrecan as a substrate. IC 50 values were 0.2 and 15 g/ml, respectively. F) Inhibition of ADAMTS5-1 (0.5 nM, F), TS5-2 (0.5 nM, E), TS5-3 (0.5 nM, ƒ), and TS5-4 (50 nM, ࡗ) by CaPPS measured using aggrecan. IC 50 values for the first 3 forms of ADAMTS-5 were 0.05 g/ml but increased 300-fold for TS5-4 (IC 50 ϭ15 g/ml).
or -5 hydrolysis of the recombinant substrate used (see Fig. 6C, D) , TIMP-3 affinity for both enzymes was markedly enhanced, and K i(app) was well below the lowest concentration of TIMP-3 used. Deletion of the C-terminal domains of ADAMTS-4 and -5 abolished this effect; ADAMTS4 -2 and ADAMTS5-4 exhibited the same K i(app) values with or without 0.05 g/ml CaPPS (K i(app) of 2.5 and 1 nM, respectively) (Fig. 7C, D) . To determine how much CaPPS improves K i(app) , the assay would have to be conducted at lower enzyme concentrations, which is not possible with currently available substrates. Lower CaPPS concentrations were also effective, with 0.5 nM ADAMTS5-1 almost completely inhibited by 0.5 nM TIMP-3 in the presence of 0.5 nM (2.5 ng/ml) CaPPS, and reducing the amount of CaPPS gave a lesser effect on the K i(app) , indicating the formation of a high affinity 1:1:1 complex. The improvement in K i(app) is therefore more than 2 orders of magnitude.
Heparin (50 ng/ml) had no effect on the interaction between TIMP-3 and aggrecanases. CaPPS (50 ng/ml) had little effect on TIMP-3 inhibition of MMP-2 or -13.
CaPPS protects Timp3
؊/؊ cartilage less effectively
Cartilage explant cultures from Timp3-null mice (36) were examined to investigate whether CaPPS protects cartilage by acting as a direct aggrecanase inhibitor or by increasing the amount and effectiveness of TIMP-3. Stimulation of cartilage from wild-type and Timp3
Ϫ/Ϫ mice with IL-1␣-induced cartilage degradation and release of aggrecan fragments into the medium (Fig.  8) . CaPPS protected wild-type mouse cartilage as effectively as porcine cartilage, with almost total protection at 50 g/ml CaPPS. Timp3 Ϫ/Ϫ cartilage, however, was markedly less protected by CaPPS. This indicates that effective protection against aggrecan degradation by CaPPS requires the presence of endogenous TIMP-3.
DISCUSSION
CaPPS and its sodium form have shown chondroprotective activities in various animal models of OA (20) . Its medical use has been approved for treatment of canine OA in a number of countries, including the United Kingdom, Finland, Canada, Australia and New Zealand, and a limited number of clinical trials in patients with OA have shown promising outcomes (19, 20) . The hallmark of OA is destruction of the cartilage matrix, primarily due to elevated activities of metalloproteinases, and therefore reduction of these proteinase activities is a potential therapeutic approach. As shown schematically in Fig. 9 , we have demonstrated that CaPPS inhibits aggrecanase activity by 3 separate but interrelated modes of action.
In this work we first demonstrated that CaPPS allows TIMP-3 to accumulate in cartilage. TIMP-3 is an important regulator of cartilage matrix catabolism. Recent studies by Sahebjam et al. (39) showed increased collagen and proteoglycan degradation in cartilage of aging Timp3 Ϫ/Ϫ mice compared with wild-type animals. Al- Figure 8 . CaPPS protects Timp3 Ϫ/Ϫ cartilage less effectively. Femoral head cartilage explants from 3-wk-old wild-type and Timp3-null mice were cultured for 3 d in the presence of 10 ng/ml IL-1␣ and/or CaPPS. Aggrecan fragments released into the medium were analyzed using the 2-B-6 antibody. though some TIMP-3 is present in the cartilage matrix, the level is insufficient to inhibit the elevated aggrecanase activity induced by IL-1␣ treatment. Our studies have shown that the low level of TIMP-3 in cartilage is due to its rapid internalization by the cell via LRPmediated endocytosis. CaPPS increases the amount of TIMP-3 in cartilage by sequestering the inhibitor extracellularly and preventing its internalization. A number of lysine and arginine residues are present in TIMP-3, mostly clustered on the opposite side from the metalloproteinase inhibitory ridge of the inhibitor. Negatively charged CaPPS most likely interacts with this patch of basic residues. LRP internalizes a large number of diverse ligands, including ␣ 2 -macroglobulinproteinase complexes, TIMP-2, MMP-2, -9, and -13, as well as several serine proteinases and their inhibitors (38) and thus regulates proteinase activity in the extracellular environment. Some LRP ligands are thought to bind initially to another cell surface receptor before being internalized by LRP. For some ligands the initial receptor is thought to be a heparan sulfate proteoglycan (38) . Because both heparin and CaPPS block TIMP-3 internalization, TIMP-3 likely also binds first to such a heparan sulfate proteoglycan coreceptor before being internalized by LRP. Our present studies have also revealed that CaPPS is an exosite inhibitor of ADAMTS-4 and -5. Domain deletion studies indicated that the effect of CaPPS is domain specific, that is, inhibition requires the Sp domain of ADAMTS-4 and the CysR domain of ADAMTS-5. Binding of CaPPS to these specific domains impairs their function by competing with their binding to aggrecan. Our previous studies showed that the Sp domain of ADAMTS-4 and the CysR domain of ADAMTS-5 play crucial roles in aggrecanolytic activity, and deletion of these domains reduces aggrecan hydrolysis by more than 95%, while having only minor effects on hydrolysis of nonaggrecan substrates such as fibromodulin and S-carboxymethylated transferrin (15, 16) , implying that these domains interact with the sulfated glycosaminoglycan chains of aggrecan. Indeed, CaPPS inhibition demonstrated high substrate specificity, with the activity of the 2 aggrecanases against the E. coliexpressed recombinant IGD substrate not inhibited by CaPPS at all in the case of ADAMTS-4 or only weakly inhibited at much higher concentrations in the case of ADAMTS-5. These results confirm that CaPPS is a true exosite inhibitor of ADAMTS-4 and -5, and, as far as we are aware, it is the first example of its kind.
Another important finding in this work is that CaPPS greatly enhances the interaction of TIMP-3 with ADAMTS-4 and -5. This enhancement is so marked that we were unable to determine K i(app) using the current assay systems. In the absence of CaPPS, TIMP-3 concentrations below the K i(app) values inhibited equimolar concentrations of ADAMTS-4 and -5 by 30 -40%. However, in the presence of CaPPS, these concentrations of TIMP-3 almost completely inhibited equimolar concentrations of ADAMTS-4 and -5, indicating that CaPPS improved the K i by at least 2 orders of magnitude (35) . Again, this effect of CaPPS was seen only for ADAMTS-4 containing the Sp domain and ADAMTS-5 containing the CysR domain. Wayne et al. (40) reported that aggrecan (10 g/ml) increases the affinity of TIMP-3 for ADAMTS-4 4-fold, and heparin (100 g/ml) has been shown to improve TIMP-3 inhibition of ADAMTS-2 and MMP-2 by 3-to 4-fold (41, 42) . These 2 sulfated polysaccharides thus have much weaker effects on TIMP-3/ ADAMTS association than CaPPS. Compared with CaPPS, heparin has only a minimal effect on aggrecanase-TIMP-3 interactions. Heparin, on the other hand, greatly improves antithrombin III inhibition of thrombin by 2 complementary mechanisms. First, heparin acts as a "template" and brings the enzyme and inhibitor into proximity, increasing the likelihood of their interaction (43) . Second, heparin induces a conformational change in the inhibitor that favors enzyme inhibition (44) . Electrostatic and steric constraints stagger sequential xylopyranose rings of CaPPS by 180°relative to each other, forming 2 negatively charged "faces" (20) . This probably enables CaPPS to bind to 2 proteins simultaneously, a property that may underpin its ability to increase TIMP-3 interaction with ADAMTS-4 and -5.
CaPPS caused a 3.5-fold increase in TIMP-3 levels in porcine cartilage. The effect of such a relatively modest change in inhibitor concentration on net enzyme activity depends on the ratio between the enzyme concentration in the tissue and K i (35) . If the concentrations of ADAMTS-4 and -5 in cartilage are much less than the K i value, then a 3.5-fold increase in TIMP-3 would not greatly affect aggrecanase activity. However, if the enzyme concentration is close to or higher than K i , then modest changes in TIMP-3 concentration would substantially affect enzyme activity (35) . CaPPS decreased the K i of TIMP-3 for ADAMTS-4 and -5 by at least 2 orders of magnitude, resulting in an increase in the ratio of enzyme to K i by at least 100-fold. This means not only that the sensitivity of the enzymes to inhibition by TIMP-3 increases, but also that small changes in TIMP-3 concentration can greatly affect enzyme activity, making CaPPS a potent enhancer of the interaction between the aggrecanases and TIMP-3. This increased affinity was not observed for MMP-1, -13, or -14. The cartilage protective effect of CaPPS is thus due both to its ability to increase the amount of TIMP-3 and to enhance its affinity for ADAMTS-4 and -5.
It is likely that inhibition of metalloproteinases by TIMP-3 takes place pericellularly as TIMP-3 is readily taken up the cell. CaPPS shifts the proteolytic balance to inhibitory by maintaining a higher concentration of extracellular TIMP-3 and by enhancing TIMP-3 affinity for the aggrecanases. Immediately after secretion, ADAMTS-4 and -5 are good targets for TIMP-3 because they still maintain their C-terminal ancillary domains. In Timp3 Ϫ/Ϫ cartilage, CaPPS works only as an exosite inhibitor of aggrecanases. In the absence of TIMP-3, ADAMTS-4 and -5 are more readily processed to shorter forms by local proteolysis (45) or autolysis (46, 47) . These shorter forms would be released from the pericellular region into the interterritorial region of the tissue (15, 16) . Although shorter forms of ADAMTSs have less aggrecanase-degrading activity than the full-length enzymes, they are also less sensitive to inhibition by CaPPS. This may be one of the reasons why we detected aggrecan degradation in Timp3 Ϫ/Ϫ cartilage even in the presence of a high concentration of CaPPS.
OA is the world's most common musculoskeletal disease and has a substantial impact on the quality of life of an increasingly aging population, but no diseasemodifying drugs are yet available. CaPPS has shown promising results in small-scale human OA trials (18, 19) . In this study we have resolved that it reduces cartilage matrix breakdown by 3 concerted modes of action and alters the balance between aggrecanases and TIMP-3. CaPPS is a unique prototypic drug to protect cartilage from degradation. Future structural studies to elucidate how CaPPS interacts with TIMP-3 and aggrecanase exosites will provide new insights into designing novel types of OA disease-modifying agents.
